将非同源(non-identical)的正常人的骨髓细胞转移给病人,称之同种异体骨髓移植,现已在临床上应用于治疗先天性免疫缺陷,再生障碍性贫血(以下简称再障)和白血病。白血病基金会上星期在伦敦组织了一次骨髓移植“一日”科学会议,认识到在前二种情况中已取得的成功,并指出在第三种情况中的进展。虽骨髓移植的技术并不复杂,只要从供体的胸骨和髂(?)多处抽吸骨髓,并立即从静脉内输给患者即可,但其并发症仍值得重视,且在三种临床情况中颇有差异。Good 复习了用相配的亲属供体骨髓作移植 Non-identical normal human bone marrow cells transferred to patients, called allogeneic bone marrow transplantation, is now clinically used to treat congenital immunodeficiency, aplastic anemia (hereinafter referred to as aplastic anemia) And leukemia. Last week the Leukemia Foundation organized a “one-day” scientific conference on bone marrow transplantation in London, recognizing the successes achieved in the first two cases and pointing to progress in the third. Although the technique of bone marrow transplantation is not complicated, as long as the bone marrow is aspirated from the donor’s sternum and iliac (?) Multiple sites and is immediately delivered intravenously to the patient, its complications are still worthy of attention. In three clinical settings The situation is quite different. Good reviewed the donor’s bone marrow for matching transplant